Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process

Vox Sanguinis

Volumn 91, Issue 2, 2006, Pages 119-125

  Furuya, Kenji ^a   Murai, Katsushi ^a   Yokoyama, Takeshi ^a   Maeno, Hideki ^a   Takeda, Yoshio ^a   Murozuka, Takashi ^a   Wakisaka, Akemi ^a   Tanifuji, Masaaki ^a   Tomono, Tsugikazu ^a  

^a Japanese Red Cross Society   (Japan)

Author keywords

20 nm pore size filter; Factor VIII; Small non enveloped viruses

Indexed keywords

BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; FILTER; FILTRATION; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE; VIRUS;

FACTOR VIII; FILTRATION; HUMANS; PERMEABILITY; VIRION; VIRUS DISEASES; VIRUS INACTIVATION; VIRUSES;

EID: 33746412347     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00792.x     Document Type: Article

References (24)

1. Tomono T, Murokawa H, Minegishi K, Yamanaka R, Iizuka HY, Miyamoto M, Satoh S, Nakahira S, Murozuka T, Emura H, Doi Y, Mine H, Yokoyama S, Ohnuma H, Tanaka T, Yoshizawa A, Nishioka K; Japanese Red Cross NAT Screening Research Group: Status of NAT screening for HCV, HIV and HBV: experience in Japan. Dev Biol (Basel) 2002; 108:29-39
2. Mine H, Emura H, Miyamoto M, Tomono T, Minegishi K, Murokawa H, Yamanaka R, Yoshizawa A, Nishioka K; Japanese Red Cross NAT Screening Research Group: High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods 2003; 112:145-151
3. Sakata H, Ihara H, Sato S, Ikeda H, Sekiguchi S: Efficiency of donor screening for human parvovirus B19 by receptor-mediated hemagglutination assay method. Vox Sang 1999; 77:197-203
4. Wakamatus C, Takakura F, Kojima E, Kiriyama Y, Goto N, Matsumoto K, Oyama M, Sato H, Okochi K, Maeda Y: Screening of blood donors human parvovirus B19 and characterization of the results. Vox Sang 1999; 76:14-21
5. Takeda Y, Wakisaka A, Noguchi K, Murozuka T, Katsubayashi Y, Matsumoto S, Tomono T, Nishioka K: Receptor-mediated haemagglutination screening and reduction in the viral load of parvovirus B19 DNA in immunopurified Factor VIII concentrate (Cross Eight M®). Vox Sang 2001; 81:266-268
6. Horowitz B, Wiebe ME, Lippin A, Vandersade J, Stryker MH: Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combiations. Tranfusion 1985; 25:516-522
7. Ishikawa G, Hisaaki T, Manabe S, Umematsu S, Yamamoto N: Novel determination method of size of virus in solution using cuprammonium regenerated cellulose membrane (BMM). Membrane 1991; 16:376-386
8. Anon: Registry of Clotting Factor Concentrates. Pharmacy Practice News 2005; 00:22-41
9. Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on Plasma-Derived Medicinal Products. CPMP/BWP/269/95, rev. 3. London, the European Agency for the Evaluation of Medicinal Products, 2001
10. Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses. CPMP/BWP/268/95. London, the European Agency for the Evaluation of Medicinal Products, 1996
11. Porzio MA, Pearson AM: Improved resolution of myofibrillar proteins with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochem Biophys Acta 1977; 490:27-34
12. Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AAJ, de Vries S, Roosendaal G, van den Berg HM, Lelie PN: Vox Sang 1998; 74:225-227
13. Wu C, Mason B, Jong J, Erdman D, Mckernan L, Oakley M, Soucie M, Evatt B, Yu M: Parvovirus B19 transmission by a high-purify factor VIII concentrate. Transfusion 2005; 45:1003-1010
14. Tateishi J, Kitamoto T, Mohri S, Satoh S, Sato T, Shepherd A, Macnaughton MR: Scrapie removal using Planova® virus removal filters. Biologicals 2001; 29:17-25
15. Hoyer LW: The factor VIII complex: structure and function. Blood 1981; 58:1-13
16. Eaton D, Rodriquez H, Vehar GA. Proteolytic processing of human factor VIII: Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25:505-512
17. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of activated human factor VIII procoagulant protein by activated protein C and its analogy to factor V. Blood 1984; 63:486-489
18. Fay PJ, Smudzin TM, Walker FJ: Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. J Biol Chem 1991; 266:20139-20145
19. André JV, Stefan JK, Marijke HV, Bonno NB, Jan JS: The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85:3150-3157
20. Ohmori K, Fretto LJ, Harrison RL, Switzer ME, Erickson HP, McKee PA: Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. J Cell Biol 1982; 95:632-640
21. 2. Proc NatL Acad Sci USA 1973; 70:2326-2329
22. Tran TH, Duckert F: Dissociation of factor VIII procoagulant antigen FVIII:CAg and factor VIII related antigen VIIIR:Ag by EDTA influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag. Thromb Haemost 1983; 50:547-551
23. Peake IR, Bloom AL: The dissociation of factor VIII by reducing agents, high salt concentration and affinity chromatography. Thromb Haemost 1976; 35:191-201
24. Siedlecki CA, Lestini BJ, Marchant KK, Eppell SJ, Wilson DL, Marchant RE: Shear-dependent change in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88:2939-2950